Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use? (Q33396453)

26 July 2017

1 reference

title

Platelet concentrates from whole-blood donations (buffy-coat) or apheresis: which one to use? (English)

1 reference

reason for deprecated rank

26 July 2017

Concentrados de plaquetas procedentes de sangre total (buffy coat) u obtenidos por aféresis; ¿qué producto emplear? (Spanish)

marking inconsistent with the registered/official identifier/name

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21807386

8 December 2024

buffy coat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21807386

8 December 2024

José Rivera

0 references

María Luisa Lozano

0 references

Vicente Vicente

0 references

language of work or name

Spanish

0 references

publication date

31 July 2011

1 reference

full work available at URL

26 July 2017

https://api.elsevier.com/content/article/PII:S0025775311006749?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

https://api.elsevier.com/content/article/PII:S0025775311006749?httpAccept=text/plain

8 December 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

1 reference

26 July 2017

volume

138

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

528-533

1 reference

An update on platelet transfusion in hematooncology supportive care

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

A critical comparison of platelet preparation methods

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Use of random versus apheresis platelet concentrates

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Summary of the AABB Interorganizational Task Force on Bacterial Contamination of Platelets: Fall 2004 impact survey.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Transfusión de plaquetas, ¿concentrados procedentes de un único o de múltiples donantes?

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

In vitro changes of platelet parameters: lessons from blood banking

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Relative safety of buffy coat platelet pools

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Elimination and multiplication of bacteria during preparation and storage of buffy coat-derived platelet concentrates.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

A General Change of the Platelet Transfusion Policy from Apheresis Platelet Concentrates to Pooled Platelet Concentrates is Associated with a Sharp Increase in Donor Exposure and Infection Rates

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Emerging infectious disease agents and their potential threat to transfusion safety

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Microsporidiosis in travelers with diarrhea from the tropics

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Complications of donor apheresis.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

The safety profile of automated collections: an analysis of more than 1 million collections

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Randomized placebo‐controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Adverse events in platelet apheresis donors: A multivariate analysis in a hospital-based program

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Thrombopoietin induces p-selectin expression on platelets and subsequent platelet/leukocyte interactions

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Thrombopoietin increases platelet adhesion under flow and decreases rolling

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Reproductive and developmental toxicity of phthalates

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Di(2-ethylhexyl)phthalate (DEHP) exposure of voluntary plasma and platelet donors.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Willingness to pay for a quality-adjusted life year: in search of a standard

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.MEDCLI.2011.05.008

8 December 2024

Identifiers

1 reference

26 July 2017

1 reference